| X-linked agammaglobulinemia
Cuvitru vs HyQvia
Side-by-side clinical, coverage, and cost comparison for x-linked agammaglobulinemia.Deep comparison between: Cuvitru vs Hyqvia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHyqvia has a higher rate of injection site reactions vs Cuvitru based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hyqvia but not Cuvitru, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cuvitru
Hyqvia
At A Glance
SC injection
Daily to every 2 weeks
Immune globulin replacement (IgG)
SC injection
Every 3-4 weeks
Immune globulin (IgG replacement)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC infusion administered daily to every 2 weeks; patients switching from IGIV begin 1 week after last IGIV dose with initial weekly dose (g) = previous IGIV dose (g) x 1.30 divided by weeks between IGIV doses; patients switching from IGSC use the same weekly dose; monitor serum IgG trough levels to guide adjustments.
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 600 mg/kg SC every 3 to 4 weeks after initial ramp-up from 1-week to full dose; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose at each infusion site.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Same dose and frequency as prior IGIV treatment SC, typical dosing interval 4 weeks; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose; ramp-up recommended based on tolerability.
Contraindications
- Previous anaphylactic or severe systemic hypersensitivity reaction to subcutaneous administration of human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
- History of anaphylactic or severe systemic reactions to IgG administration
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Known systemic hypersensitivity to hyaluronidase including rHuPH20
- Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)
Adverse Reactions
Most common (>=5%) Local adverse reactions, headache, nausea, fatigue, diarrhea, vomiting
Postmarketing Aseptic meningitis, anaphylactic reaction, tachycardia, tremor, paresthesia, dyspnea, laryngospasm, injection site reaction (induration, warmth), chest discomfort
Most common (>5%) Local infusion site reactions (discomfort/pain, erythema, swelling/edema, pruritus), headache, fatigue, nausea, pyrexia, vomiting
Postmarketing Hypersensitivity, influenza-like illness, infusion site leaking, anaphylactic reaction, tremor, tachycardia, hypotension, infusion related reaction, dyspnea, paresthesia oral, dermatitis allergic, injection site rash, alanine aminotransferase increased
Pharmacology
CUVITRU is a human IgG replacement product that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, restoring abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.
Immune globulin (IgG) replacement product in which the Immune Globulin Infusion (Human), 10% supplies broad-spectrum opsonizing and neutralizing IgG antibodies against bacterial and viral agents, while rHuPH20 transiently depolymerizes subcutaneous hyaluronan to increase tissue permeability, facilitating dispersion and absorption of the full IgG dose administered subcutaneously.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cuvitru
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
Hyqvia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Cuvitru
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (1/8)
Hyqvia
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cuvitru
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Hyqvia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CuvitruView full Cuvitru profile
HyqviaView full Hyqvia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.